Target intelligence / Profile preview

Small integral membrane protein 1 (SMIM1)

Target
SMIM1
Molecular classification
Integral membrane protein, Type II transmembrane protein, Tail-anchored protein
01

Overview

Small integral membrane protein 1 (SMIM1) is a 78-amino acid single-pass transmembrane protein encoded on chromosome 1, serving as the carrier for the Vel blood group antigen on red blood cells[1][2][4][5][6][7]. The Vel antigen is of high frequency, but rare individuals lack its expression due to homozygous deletions or mutations in SMIM1, and these Vel-negative individuals can develop anti-Vel antibodies resulting in hemolytic transfusion reactions[2][4][6]. SMIM1 is predominantly expressed in hematopoietic cells and is post-translationally modified; its membrane orientation is tail-anchored, with the C-terminus extracellular and most of the protein cytoplasmic[1][3][4]. Despite its clinical importance in transfusion medicine, the precise physiological role of SMIM1 in erythropoiesis and red cell biology remains poorly understood[1][4][7]. No therapeutics target SMIM1, but genetic and serological identification is crucial for safe blood transfusion practices[2][4][5][6].

Other names
Vel blood group antigenVelblood group VEL proteinVel protein
02

Mechanism of action

null (no drugs act by modulating SMIM1)

03

Biological functions

Carrier of the Vel antigen (blood group determinant)Regulator of red blood cell formation (erythropoiesis, mechanism not fully determined)Undergoes post-translational phosphorylation
04

Disease associations

Hemolytic transfusion reactions (caused by anti-Vel antibodies in Vel-negative individuals)Other: no direct evidence for other disease roles, not implicated in cancer, infection, or general pathophysiology outside transfusion medicine
05

Safety considerations

Severe and sometimes fatal hemolytic transfusion reaction due to anti-Vel antibodies in Vel-negative patients receiving Vel-positive bloodTransfusion risk requires precise molecular typing and matching
06

Biomarkers

SMIM1 gene deletions (e.g., homozygous 17-bp deletion)Vel antigen presence/absence for blood typing

Beyond the preview

Go deeper on Small integral membrane protein 1 (SMIM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small integral membrane protein 1 (SMIM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call